
Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
Hematologic Oncology Update
00:00
The Benefits of a Caliber BTK Inhibitor
The one thing that a caliber may have, and its advantage is the hypertension signal. We saw slightly lower rates of hemorrhage and bruising bleeding in the elevate study comparatively to Xanabrutin. But again, this is where these kind of indirect comparison studies with common denominators, roll arms are going to be valuable because we may never see these true head to head Cala versus Xanu study ever.
Transcript
Play full episode